About Captozyme
Captozyme is a company based in Alachua (United States) founded in 2009 was acquired by Arranta Bio in November 2019.. Captozyme has raised $3.4 million across 6 funding rounds from investors including HHS, Arranta Bio and Florida Institute. Captozyme offers products and services including RNA Manufacturing, Plasmid Manufacturing, Viral Vector Manufacturing, and ATMP Fill and Finish. Captozyme operates in a competitive market with competitors including Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Alebund and Aurinia Pharmaceuticals, among others.
- Headquarter Alachua, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Captozyme Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.4 M (USD)
in 6 rounds
-
Latest Funding Round
$3.4 M (USD), Series A
Sep 23, 2016
-
Investors
HHS
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Arranta Bio
(Nov 13, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Captozyme
Captozyme offers a comprehensive portfolio of products and services, including RNA Manufacturing, Plasmid Manufacturing, Viral Vector Manufacturing, and ATMP Fill and Finish. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Manufactures RNA therapies for pharmaceutical applications.
Produces plasmid DNA for biologics development.
Handles production of viral vectors for gene therapies.
Provides finishing services for advanced therapy medicinal products.
Unlock access to complete
Unlock access to complete
Funding Insights of Captozyme
Captozyme has successfully raised a total of $3.4M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.4 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $3.4M
-
First Round
First Round
(01 Apr 2010)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2016 | Amount | Series A - Captozyme | Valuation |
investors |
|
| Jan, 2011 | Amount | Grant - Captozyme | Valuation |
investors |
|
| Sep, 2010 | Amount | Grant - Captozyme | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Captozyme
Captozyme has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Arranta Bio and Florida Institute. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support is provided for Florida's technology ventures and innovation.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Developer of therapeutics for microbiome based diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Captozyme
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Captozyme
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Captozyme Comparisons
Competitors of Captozyme
Captozyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Unicycive, Akebia Therapeutics, Alebund and Aurinia Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| domain | founded_year | HQ Location |
Therapeutics for renal diseases are developed and launched by Renalys.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Captozyme
When was Captozyme founded?
Captozyme was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Where is Captozyme located?
Captozyme is headquartered in Alachua, United States. It is registered at Alachua, Florida, United States.
Is Captozyme a funded company?
Captozyme is a funded company, having raised a total of $3.4M across 6 funding rounds to date. The company's 1st funding round was a Grant of $1.16M, raised on Apr 01, 2010.
What does Captozyme do?
Captozyme is a preclinical stage biotechnology company focussed on developing enzyme-based products for the dietary management of kidney stones and hyperoxaluria. It is developing its programs which enhance foods to reduce intake of oxalate which are the building block of up to 75 of all kidney stones. It claims that its enzymes removes oxalate from different food products and can also be added directly to your food to control and balance your oxalate intake. It is also planning to develop a product pipeline for hyperoxaluria.
Who are the top competitors of Captozyme?
Captozyme's top competitors include Calliditas Therapeutics, Akebia Therapeutics and Gennova.
What products or services does Captozyme offer?
Captozyme offers RNA Manufacturing, Plasmid Manufacturing, Viral Vector Manufacturing, and ATMP Fill and Finish.
Who are Captozyme's investors?
Captozyme has 3 investors. Key investors include HHS, Arranta Bio, and Florida Institute.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.